Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC By Ogkologos - July 22, 2025 399 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CREST study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR The Evidence Is In: COVID Vaccines Do Protect Patients With Cancer... September 20, 2021 Exercising Safely During Breast Cancer Treatment: What to Know October 27, 2022 Neoadjuvant Dabrafenib Plus Trametinib Has High Pathological Response Rates in Clinical... May 24, 2024 Shelter Puppies Got A Private Tour Of The Georgia Aquarium March 31, 2020 Load more HOT NEWS Study Reinforces Treatment Idea for Cancer with Microsatellite Instability Radio Hosts Test Sanity For Charity By Listening to ‘Baby Shark’... Data from a Large Cohort of Patients with mRCC Demonstrate the... Early Evaluation of Nutritional Status Is Needed to Provide Nutritional Support...
